Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

The efficacy-toxicity conundrum: breaking the mold

Louis F. Diehl

Blood (2020) 135 (10): 704–706.

https://doi.org/10.1182/blood.2019004464

Published: 2020

Journal Articles

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Ko Ko Ko Maung, MD, Mohammad Chaudhry, MD, Yi Ren, MS, Sin-Ho Jung, PhD, Kristi M. Romero, BS, Kelly Corbet, BS, Nelson J. Chao, MD, Taewoong Choi, MD, Anna Mae Diehl, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Mitchell E. Horwitz, MD, Gwynn D. Long, MD, Richard D. Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Keith Sullivan, MD, Mustafa R. Bashir, MD, Anthony D. Sung, MD

Blood (2019) 134 (Supplement_1): 5731.

https://doi.org/10.1182/blood-2019-121830

Published: 2019

Journal Articles

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

Anthony D. Sung, MD, Carlos M. de Castro, MD, Thomas W. LeBlanc, MD MA, Gwynn D. Long, MD, Donna B. Adams, NP, Danielle M. Brander, MD, Sandeep Dave, MD, Louis F. Diehl, MD, Phuong Linh Doan, MD, Therese Hennig, PA, Yubin Kang, MD, Matthew S. McKinney, MD, Lindsay A.M Rein, MD, Dorothy A. Sipkins, MD, Yiping Yang, MD PhD, Nelson J. Chao, MDM.B.A, David A. Rizzieri, MD

Blood (2017) 130 (Supplement 1): 3853.

https://doi.org/10.1182/blood.V130.Suppl_1.3853.3853

Published: 2017

Journal Articles

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Cristina Gasparetto, MD, Michael Green, MD, Anandgopal Srinivasan, MDcal Student, Yubin Kang, MD, David A. Rizzieri, MD, Carlos Decastro, MD, Louis F. Diehl, MD, Anne Beaven, MD, Zighuo Li, PhD, Arati V. Rao, MD, Anderson Garrett, Sascha Tuchman, MD, Gwynn D. Long, MD

Blood (2015) 126 (23): 1857.

https://doi.org/10.1182/blood.V126.23.1857.1857

Published: 2015

Journal Articles

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Danielle M. Brander, MD, Anne W Beaven, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Thomas C. Shea, MD, Carlos deCastro, Joseph O. Moore, MD, David A. Rizzieri, MD

Blood (2012) 120 (21): 1626.

https://doi.org/10.1182/blood.V120.21.1626.1626

Published: 2012

Journal Articles

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Arati Rao, MD, David A. Rizzieri, MD, Eduardo Vanegas, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4948.

https://doi.org/10.1182/blood.V120.21.4948.4948

Published: 2012

Journal Articles

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Arati Rao, MD, Ghazi Khan, David A. Rizzieri, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4935.

https://doi.org/10.1182/blood.V120.21.4935.4935

Published: 2012

Journal Articles

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Anne W Beaven, MD, David A. Rizzieri, MD, Zachary Powell, Zhiguo Li, PhD, Peggy Alton, RN, Julie Warzecho, RN, Louis F. Diehl, MD, Joseph O. Moore, MD, Carlos Manuel de Castro, III, MD, Jon P. Gockerman, MD

Blood (2011) 118 (21): 2681.

https://doi.org/10.1182/blood.V118.21.2681.2681

Published: 2011

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Carlos Manuel de Castro, III, MD, Donna Adams, RN, Arati V Rao, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Julie Warzecho, RN, David A. Rizzieri, MD

Blood (2011) 118 (21): 5029.

https://doi.org/10.1182/blood.V118.21.5029.5029

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells

J. Brice Weinberg, MD, David J. DiLillo, PhD, Yohei Iwata, PhD, Takashi Matushita, PhD, Karen M. Matta, BS, Guglielmo M. Venturi, PhD, Giandomenico Russo, MD, PhD, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Alicia D. Volkheimer, MS, Daphne R. Friedman, M.D., Mark C Lanasa, MD, PhD, Russell P. Hall, MD, Thomas J. Tedder, PhD

Blood (2011) 118 (21): 286.

https://doi.org/10.1182/blood.V118.21.286.286

Published: 2011

Journal Articles

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

Lauren Held, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos Manuel de Castro, III, MD, Joseph O. Moore, MD, David A. Rizzieri, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Nelson J. Chao, MD, Cristina Gasparetto, MD

Blood (2011) 118 (21): 5129.

https://doi.org/10.1182/blood.V118.21.5129.5129

Published: 2011

Journal Articles

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Dale J. Christensen, Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, Mark C. Lanasa, Daphne R. Friedman, Barbara K. Goodman, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Michael P. Vitek, J. Brice Weinberg

Blood (2011) 118 (15): 4150–4158.

https://doi.org/10.1182/blood-2011-04-351072

Published: 2011

Includes: Supplemental data

Journal Articles

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Dale J. Christensen, PhD, Jessica Oddo, B.S., Karen Bond, Alicia Volkheimer, M.S., Youwei Chen, MD, Evan Davis, BS, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos de Castro, III, MD, Joseph O. Moore, MD, Michael P Vitek, PhD, J. Brice Weinberg, MD

Blood (2010) 116 (21): 4190.

https://doi.org/10.1182/blood.V116.21.4190.4190

Published: 2010

Journal Articles

Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.

Daphne R Friedman, MD, Jeremy D Harrison, MD, Lindsay A Magura, MD, Holly A Warren, MD, Louis F Diehl, MD, J. Brice Weinberg, MD

Blood (2009) 114 (22): 2344.

https://doi.org/10.1182/blood.V114.22.2344.2344

Published: 2009

Journal Articles

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Dale J. Christensen, PhD, Karen M. Bond, BS, Alicia D. Volkheimer, MS, Jessica Oddo, BS, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, Michael P. Vitek, PhD, J. Brice Weinberg, MD

Blood (2009) 114 (22): 802.

https://doi.org/10.1182/blood.V114.22.802.802

Published: 2009

Journal Articles

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Cristina Gasparetto, MD, Jon P Gockerman, Louis F Diehl, MD, Carlos de Castro, III, MD, Joseph O Moore, Gwynn D Long, Mitchell Horwitz, MD, John Chute, MD, Keith M Sullivan, MD, Rachel Neuwirth, Patricia H Davis, Linda M. Sutton, Russell D Anderson, Nelson Chao, David A. Rizzieri, MD

Blood (2008) 112 (11): 3325.

https://doi.org/10.1182/blood.V112.11.3325.3325

Published: 2008

Journal Articles

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Blood (2008) 112 (11): 359.

https://doi.org/10.1182/blood.V112.11.359.359

Published: 2008

Journal Articles

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

J. Brice Weinberg, MD, Ning Jiang, MD, Alicia D. Volkheimer, MS, Youwei Chen, MD, Karen M. Bond, BS, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, David A. Rizzieri, MD, PhD, Marc C. Levesque, MD, PhD, Kenneth Mugridge, PhD, Joe DeAngelo

Blood (2007) 110 (11): 3129.

https://doi.org/10.1182/blood.V110.11.3129.3129

Published: 2007

NARROW

The efficacy-toxicity conundrum: breaking the mold

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only